论文部分内容阅读
为探讨异常黑胆质成熟剂对异常黑胆质型肝癌病证大鼠模型肝脏形态学的影响,按照维吾尔医模型建立标准,采用干寒环境、干寒饲料和异常物理刺激等多重因素复合作用,建立维医异常黑胆质证载体动物模型,在此基础上,通过饮用灭菌食用水配制浓度为0.1 mg/m L二乙基亚硝胺(DEN)溶液建立异常黑胆质型肝癌病证载体大鼠模型,并用大、中、小不同剂量(6.0、3.0、1.5 g/kg)异常黑胆质成熟剂进行全程干预,共分为病证模型组、小剂量组、中剂量组、大剂量组、正常对照组、肝癌对照组6组,每组24只。干预20周时处死大鼠,对肝脏的病理变化和超微结构进行观察。研究发现,20周时,低剂量组与病证模型组相比,形态无明显差异,高剂量组和中剂量组与病证模型组相比,具有肝细胞结缔组织增生减少、间质炎性细胞浸润程度明显减轻、肝细胞水肿程度减轻等病理表现及肝细胞内细胞器分布不均匀、肝糖原和线粒体逐渐减少等超微结构明显变化。研究表明,异常黑胆质成熟剂对异常黑胆质型肝癌病证模型的肝脏组织形态改变有一定的保护和修复作用。
In order to investigate the effect of abnormal savda mature agent on liver morphology in rats with abnormal savda hepatocellular carcinoma, according to the Uyghur medical model to establish the standard, using dry and cold environment, dry and cold feed and abnormal physical stimulation and other multiple factors combined effect , To establish an animal model of abnormal Savanna syndrome cardioplegia. On this basis, to establish an abnormal savda hepatocarcinoma syndrome by preparing a solution of diethylnitrosamine (DEN) at a concentration of 0.1 mg / m L by drinking sterilized drinking water The rat model was induced by different doses (6.0,3.0,1.5 g / kg) of abnormal savda. The rats were divided into two groups: model group, low dose group, medium dose group, Dose group, normal control group, liver cancer control group 6, each group 24. Rats were sacrificed at 20 weeks after intervention, and pathological changes and ultrastructure of the liver were observed. The study found that there was no significant difference in morphology between the low-dose group and the syndrome-lesion model group at 20 weeks. Compared with the model group, the high-dose group and the medium-dose group had less hepatocyte connective tissue hyperplasia and interstitial inflammatory The degree of cell infiltration was significantly reduced, the extent of hepatocyte edema alleviated and other pathological findings and heterogeneous distribution of organelles within the hepatocytes, hepatic glycogen and mitochondria gradually decreased and other ultrastructural changes. Studies have shown that the abnormal savda mature agent on the abnormal savda hepatocellular carcinoma syndrome model liver tissue morphological changes have some protection and repair.